Taking aim at Ewing's sarcoma: Is KIT a target and will imatinib work?

Journal of the National Cancer Institute

Volumn 94, Issue 22, 2002, Pages 1660-1661

  Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; ENZYME INHIBITION; EWING SARCOMA; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037146228     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.22.1660     Document Type: Editorial

References (19)

1. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9.
2. Landuzzi L, De Giovanni C, Nicoletti G, Rossi I, Ricci C, Astolfi A, et al. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol 2000;157:2123-31.
3. Ricotti E, Fagioli F, Garelli E, Linari C, Crescenzio N, Horenstein AL, et al. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 1998;91:2397-405.
4. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
5. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
6. Hotfilder M, Lanvers C, Jurgens H, Boos J, Vormoor J. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother Pharmacol 2002;50:167-9.
7. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
8. Buchdunger E, Matter A, Druker BJ. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 2001;1551:M11-8.
9. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
10. Heinrich MC, Wait CL, Yee KW, Griffith DJ. STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis. Blood 2000;96:173b.
11. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
12. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, von Mehren M, et al. KIT mutational status predicts response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc ASCO 2002;21:2a.
13. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440-8.
14. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.
15. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8.
16. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
17. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandes Reese S, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
18. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
19. Peng B, Hayes M, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, et al. Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc ASCO 2001;20:280a.